News & Events
FutuRx Launches GliXogen Therapeutics to Develop Novel Therapies for Multiple Sclerosis and Other Demyelinating Disorders
PRWEB, January 14, 2019Mitoconix Bio gets $20M for mitochondrial dysfunction in neurodegeneration
BioWorld, June 28, 2017Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
Yahoo Finance, June 27, 2017Neurological therapy co Mitoconix Bio raises $20m
Globes, June 27, 2017החברה הישראלית שגייסה 20 מיליון דולר – ורוצה להילחם בפרקינסון ואלצהיימר
TheMarker, June 27, 2017Israeli startup seeks to replace antibiotics
Globes, May 22, 2017RM Global Partners Completes $30 Million First Closing of New Israel-Based Biopharma Fund
PRNewswire, May 18, 2017RM Global to invest $30m in FutuRx biotech startups
Globes, May 18, 2017Microbiome therapeutics co BiomX raises $24m
Globes, May 15, 2017BiomX raises $24 million to boost bacteria based drugs
Times of Israel, May 15, 2017FutuRx – פיתוחים תרופתיים פורצי דרך
לשכת המדען הראשי, משרד הכלכלה, July 1, 2015FutuRx – Groundbreaking Therapeutics Developments
Israel's Innovation Magazine, July 1, 2015J&J, Takeda team up to open Israeli biotech incubator
Israel Inside, January 19, 2015FutuRx Biotech Incubator Selects First Two Projects
GLOBS, January 15, 2015The two startups are XoNovo (Alzheimer’s Disease) and Hepy Biosciences (cancer).
חממת פיוצ’רקס משקיעה בסטארט-אפ חדש של רפי גדרון
גלובס, January 15, 2015FutuRx Begins Operations in Israel
PRNewswire, January 13, 2015New biotech incubator to advance biotechnology products in Israel
First Companies Move into FutuRx Biotech Incubator in Israel
PRNewswire, January 12, 2015FutuRx, a biotechnology incubator in Weizmann Science Park, is pleased to announce that its first two biotechnology companies have started operations. The companies are developing new approaches and candidate drugs in oncology and neurodegenerative disease.